SCHEMBL25754525

SCHEMBL25754525

CC#CC(O)CCOCCC(N)CCN1CCCCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.32
LMNA P02545 2/20 0.32
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM5 P08912 1/20 0.30
CYP2D6 P10635 1/20 0.30
THRB P10828 1/20 0.30
CYP2C9 P11712 1/20 0.30
ADRA2C P18825 1/20 0.30
DRD4 P21917 1/20 0.30
ACHE P22303 1/20 0.30
SLC6A2 P23975 1/20 0.30
HRH2 P25021 1/20 0.30
HTR2A P28223 1/20 0.30
ADRA1A P35348 1/20 0.30
HRH1 P35367 1/20 0.30
SLC6A3 Q01959 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754504 0.92 HRH3 (0.31) HRH3LMNA
SCHEMBL25754502 0.88 LMNA (0.35) HRH3LMNAALDH1A1CYP1A2
SCHEMBL25754591 0.87 HRH3 (0.38) HRH3ALDH1A1
SCHEMBL25754249 0.87 HRH3 (0.38) HRH3ALDH1A1
SCHEMBL25754258 0.85 KDM4E (0.39) HRH3ALDH1A1
SCHEMBL25754607 0.82 HRH3 (0.43) HRH3
SCHEMBL25754614 0.82 HRH3 (0.43) HRH3
SCHEMBL25754512 0.81 KMT2A (0.36) ALDH1A1CYP2D6
SCHEMBL25754250 0.80 HRH3 (0.39) HRH3ALDH1A1CHRM2CHRM4ADRA2C
SCHEMBL25754573 0.79 HRH3 (0.38) HRH3ALDH1A1CHRM2CHRM4ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 HRH3 1596/4885LMNA 1517/4885ALDH1A1 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.